Patient Management

2074 questions

Question 1941Question →

A 5858-year-old woman is brought to the emergency department by her husband due to progressive confusion, lethargy, and a witnessed generalized tonic-clonic seizure at home. She has a history of small cell lung cancer and is currently undergoing chemotherapy. Her temperature is 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure is 134/82 mmHg134/82 \text{ mmHg}, pulse is 88/min88/\text{min}, and respiratory rate is 16/min16/\text{min}. She is somnolent but arousable to painful stimuli. Laboratory testing reveals a serum sodium concentration of 110 mEq/L110 \text{ mEq/L}, serum osmolality of 240 mOsm/kg240 \text{ mOsm/kg}, and urine osmolality of 650 mOsm/kg650 \text{ mOsm/kg}. A diagnosis of syndrome of inappropriate antidiuretic hormone secretion (SIADH) causing severe, symptomatic hyponatremia is made.

Arrange the following monitoring and therapeutic evaluation steps in the most appropriate chronological sequence for managing this patient's acute presentation.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence is to first infuse an initial bolus of 3%3\% hypertonic saline, followed by reassessing symptoms and serum sodium. If symptoms persist, subsequent boluses are administered. Once symptoms resolve or sodium rises by 5 mEq/L5 \text{ mEq/L}, the infusion is terminated. Finally, fluid restriction is initiated with periodic monitoring to ensure the 2424-hour correction limit is not exceeded.
The appropriate protocol for severe symptomatic hyponatremia begins with immediate administration of a 3%3\% hypertonic saline bolus to reverse cerebral edema. This is followed by immediate reassessment. If symptoms persist, further boluses are indicated. The aggressive phase of treatment stops as soon as severe symptoms resolve or the sodium rises by 5 mEq/L5 \text{ mEq/L}. The final phase is maintenance therapy (e.g., fluid restriction for SIADH) and ongoing monitoring to ensure the total correction does not exceed 8 mEq/L8 \text{ mEq/L} in the first 2424 hours.

Step-by-Step Solution

1
Administer initial 3%3\% hypertonic saline bolus.
Rapid mobilization of water out of brain cells, decreasing cerebral edema.
The patient is actively seizing or post-ictal with profound hyponatremia (110 mEq/L110 \text{ mEq/L}), requiring immediate life-saving intervention.
2
Check serum sodium and reassess neurologic status.
Determination of whether the initial dose successfully reversed the severe cerebral edema.
Monitoring the response is required before deciding whether to continue aggressive therapy or transition to maintenance.
3
Administer additional boluses if required.
Further correction of hyponatremia if the initial response was inadequate.
Persistent severe symptoms indicate ongoing significant cerebral edema that requires continued rapid correction.
4
Discontinue hypertonic saline.
Cessation of rapid serum sodium elevation.
A 5 mEq/L5 \text{ mEq/L} increase is typically sufficient to reverse severe cerebral edema; continuing hypertonic therapy risks osmotic demyelination syndrome.
5
Transition to fluid restriction and ongoing monitoring.
Gradual correction of the remaining hyponatremia while addressing the underlying SIADH.
To safely manage the patient over the next 2424 to 4848 hours, avoiding a correction rate greater than 8 mEq/L8 \text{ mEq/L} per day.

Key Concept

The acute management of severe symptomatic hyponatremia involves immediate boluses of 3%3\% hypertonic saline, close monitoring of clinical response, and strict cessation of hypertonic therapy once acute symptoms resolve to prevent osmotic demyelination.
Estimated Time:1m 30s
Question 1942Question →

A 67-year-old man is admitted to the hospital with a 3-day history of productive cough, fever, shortness of breath, and right-sided pleuritic chest pain. His past medical history is significant for symptomatic atrial fibrillation, heart failure with preserved ejection fraction, and type 2 diabetes mellitus. His current medications include sotalol, apixaban, metformin, and empagliflozin. He has no known drug allergies.

Vital signs are:
Temperature: 38.6∘C38.6^\circ\text{C} (101.5∘F101.5^\circ\text{F})
Blood pressure: 118/74 mmHg118/74 \text{ mmHg}
Pulse: 88/min88/\text{min}
Respirations: 28/min28/\text{min}
Oxygen saturation: 91%91\% on room air

Physical examination reveals bronchial breath sounds and crackles over the right lower lung field.

Laboratory results are as follows:
Leukocyte count: 14,500/mm314,500/\text{mm}^3 (85%85\% neutrophils)
Blood urea nitrogen: 28 mg/dL28 \text{ mg/dL}
Creatinine: 1.2 mg/dL1.2 \text{ mg/dL}

Chest radiography demonstrates a dense consolidation in the right lower lobe. An electrocardiogram shows normal sinus rhythm with a heart rate of 88/min88/\text{min} and a QTc interval of 490 ms490 \text{ ms} (normal: ≤440 ms\leq 440 \text{ ms} in men).

The patient is diagnosed with community-acquired pneumonia. Which of the following is the most appropriate empiric pharmacologic intervention for this patient?

Show answer & explanation

Answer: Intravenous ceftriaxone and oral doxycycline

Answer

Intravenous ceftriaxone and oral doxycycline
The correct intervention is intravenous ceftriaxone and oral doxycycline. This patient requires inpatient admission for community-acquired pneumonia (CAP). Standard empiric therapy for non-severe inpatient CAP consists of a beta-lactam (e.g., ceftriaxone) combined with a macrolide (e.g., azithromycin), or respiratory fluoroquinolone (e.g., levofloxacin) monotherapy. However, this patient has a significantly prolonged baseline QTc interval (490 ms) and is currently taking sotalol, a Class III antiarrhythmic known to delay ventricular repolarization. Both macrolides and fluoroquinolones can further prolong the QTc interval, placing this patient at an unacceptably high risk for life-threatening arrhythmias, specifically Torsades de Pointes. Doxycycline provides excellent atypical coverage for CAP (e.g., Mycoplasma, Legionella) and does not affect the QTc interval. Therefore, substituting the macrolide with doxycycline is the safest and most appropriate guideline-concordant modification.

Step-by-Step Solution

1
Assess the clinical presentation and diagnostic findings to confirm the diagnosis.
The patient has community-acquired pneumonia (CAP) requiring inpatient admission based on symptoms, imaging, and elevated CURB-65 criteria (age > 65, BUN > 19).
Establishing the correct diagnosis and appropriate level of care determines the initial empiric antibiotic pathways.
2
Review the patient's baseline diagnostic testing and current medication list for potential contraindications.
The electrocardiogram shows a prolonged QTc interval of 490 ms, and the medication list includes sotalol (a Class III antiarrhythmic known to prolong QTc) and apixaban (a CYP3A4/P-gp substrate).
Identifying baseline risk factors is critical before prescribing new pharmacologic interventions, particularly antibiotics with known cardiac or metabolic interactions.
3
Evaluate standard empiric antibiotic regimens for inpatient CAP against the patient's specific safety profile.
Standard therapies (beta-lactam plus macrolide, or respiratory fluoroquinolone) are unsafe because both macrolides (azithromycin, clarithromycin) and fluoroquinolones (levofloxacin) further prolong the QTc interval, risking Torsades de Pointes.
Applying safety constraints eliminates the most commonly prescribed first-line options for this specific patient.
4
Select the optimal alternative guideline-concordant regimen that avoids identified risks.
A beta-lactam (ceftriaxone) combined with doxycycline is chosen.
Doxycycline provides the necessary coverage for atypical pathogens in CAP without affecting ventricular repolarization.

Key Concept

Pharmacologic management of community-acquired pneumonia in patients with prolonged QTc intervals or taking QTc-prolonging medications.
Question 1943Question →

An occupational health physician evaluates a 28-year-old woman who is preparing to begin employment as a clinical laboratory technician, a role that involves handling human blood samples. She has a medical history of severe plaque psoriasis, which has been well controlled since initiating treatment with subcutaneous adalimumab six months ago. She has no other medical conditions. She has never smoked cigarettes and consumes alcohol occasionally. Her last cervical cancer screening with cytology was one year ago and was normal. Physical examination today reveals normal vital signs and clear skin with faint residual hyperpigmentation on the extensor surfaces. A review of her childhood immunization records confirms completion of the standard pediatric series, including two doses of the measles, mumps, and rubella vaccine. Pre-employment serological testing indicates a negative varicella-zoster virus IgG antibody and a negative hepatitis B surface antibody (anti-HBs). The patient states she never had chickenpox as a child. Which of the following is the most appropriate immunization strategy for this patient?

Show answer & explanation

Answer: Initiate the recombinant hepatitis B vaccine series and advise the patient that the varicella vaccine is contraindicated

Answer

Initiate the recombinant hepatitis B vaccine series and advise the patient that the varicella vaccine is contraindicated
The correct strategy involves initiating the recombinant hepatitis B vaccine series while advising that the varicella vaccine is contraindicated. This patient requires hepatitis B immunization due to her upcoming occupational exposure to human blood, confirmed by her negative surface antibody (anti-HBs). Hepatitis B is an inactivated, recombinant vaccine and is perfectly safe to administer to patients receiving biologic immunosuppressive therapies. In contrast, the patient is also susceptible to varicella (negative VZV IgG). The varicella vaccine is a live-attenuated virus. Adalimumab is a TNF-alpha inhibitor that induces significant systemic immunosuppression. Administration of live-attenuated vaccines (e.g., varicella, measles-mumps-rubella, intranasal influenza) to patients on biologic therapies is absolutely contraindicated due to the high risk of unregulated viral replication and potentially fatal disseminated disease.

Step-by-Step Solution

1
Evaluate occupational risk factors based on the new employment role.
The patient will handle human blood samples as a laboratory technician.
Healthcare personnel exposed to blood or body fluids must be immune to hepatitis B.
2
Assess the patient's immune status based on serology.
Negative anti-HBs and negative varicella-zoster virus (VZV) IgG.
Identifies susceptibility to both hepatitis B and primary varicella.
3
Review current medications for potential absolute contraindications to standard immunizations.
The patient is actively taking adalimumab, a tumor necrosis factor (TNF)-alpha inhibitor.
Biologic therapies induce significant immunosuppression, fundamentally altering which vaccines can be safely administered.
4
Synthesize indications and contraindications to select the appropriate vaccine strategy.
The inactivated hepatitis B vaccine is safe and indicated, but the live-attenuated varicella vaccine is contraindicated.
Live-attenuated vaccines risk causing unchecked viral replication and severe disseminated disease in immunocompromised hosts.

Key Concept

Immunization Safety in Immunocompromised Patients
Question 1944Question →

A 62-year-old man is evaluated in the intensive care unit for acute-onset dyspnea, right-sided pleuritic chest pain, and altered mental status. He is currently on postoperative day 4 following an open left hemicolectomy for a perforated diverticulum. Vital signs are temperature 37.2°C (99.0°F), blood pressure 76/42 mmHg, pulse 135/min, and respiratory rate 28/min. Oxygen saturation is 84% on a non-rebreather mask. Physical examination reveals jugular venous distension and a right ventricular heave. An urgent computed tomography pulmonary angiogram demonstrates a massive saddle pulmonary embolism extending into the bilateral main pulmonary arteries. Bedside transthoracic echocardiography shows severe right ventricular dilation with hypokinesis. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Percutaneous mechanical thrombectomy

Answer

Percutaneous mechanical thrombectomy is the most appropriate next step to rapidly relieve right ventricular outflow obstruction in a patient with massive pulmonary embolism who has an absolute contraindication to systemic thrombolysis.
The correct answer is percutaneous mechanical thrombectomy. This patient has a massive pulmonary embolism, characterized by acute right ventricular failure and obstructive shock (manifested by a blood pressure of 76/42 mmHg and altered mental status). While the standard first-line treatment for massive pulmonary embolism is systemic thrombolysis with tissue plasminogen activator (tPA), this patient is on postoperative day 4 following an open hemicolectomy. Recent major surgery (typically within the last 3 weeks) is an absolute contraindication to systemic fibrinolysis due to the unacceptably high risk of catastrophic surgical site hemorrhage. Therefore, a catheter-directed procedural intervention, such as percutaneous mechanical thrombectomy or surgical pulmonary embolectomy, is required. These interventions rapidly debulk the thrombus, reduce right ventricular afterload, and safely restore systemic hemodynamics without exposing the patient to systemic fibrinolytic agents.

Step-by-Step Solution

1
Identify the severity of the pulmonary embolism.
The patient exhibits hypotension, tachycardia, and severe right ventricular strain, classifying this as a massive (high-risk) pulmonary embolism presenting with obstructive shock.
Hemodynamic status determines whether the patient requires primary reperfusion therapy versus standard anticoagulation.
2
Assess for contraindications to standard pharmacologic reperfusion therapy.
The patient is on postoperative day 4 following a major open abdominal surgery (hemicolectomy).
Recent major surgery (within the last 3 weeks) is an absolute contraindication to systemic thrombolytic therapy like tissue plasminogen activator (tPA).
3
Select the appropriate alternative procedural intervention.
Catheter-directed mechanical thrombectomy (or surgical embolectomy) must be selected.
This procedure mechanically removes the thrombus burden, rapidly decreasing right ventricular afterload and restoring cardiac output without the catastrophic bleeding risks associated with systemic thrombolysis.

Key Concept

Massive pulmonary embolism with absolute contraindications to systemic thrombolysis requires immediate procedural intervention with percutaneous mechanical thrombectomy or surgical embolectomy.
Question 1945Question →

A 68-year-old woman is brought to the emergency department via ambulance after a witnessed generalized tonic-clonic seizure. Her husband reports that she recently started taking hydrochlorothiazide for hypertension and has been drinking large volumes of water due to medication-induced dry mouth. On presentation, she is unresponsive, and shortly after arrival, she develops a recurrent generalized tonic-clonic seizure. A point-of-care basic metabolic panel reveals a serum sodium concentration of 114 mEq/L. The physician immediately initiates management for severe symptomatic hyponatremia.

Arrange the following steps for the treatment and ongoing monitoring of this patient's condition in the most appropriate chronological sequence.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with the immediate administration of a 3% hypertonic saline bolus, followed by a rapid reassessment of symptoms and sodium levels, discontinuation of the saline once symptoms resolve, and finally, long-term serial monitoring to avoid exceeding the 24-hour correction limit.
The management of severe symptomatic hyponatremia must follow a strict and specific timeline: immediate targeted administration of 3% hypertonic saline to rapidly reverse cerebral edema, followed by rapid reassessment (within 20 minutes) to confirm a safe rise. Once the seizures resolve, hypertonic therapy must be discontinued promptly to avoid rapid overcorrection. Finally, strict serial monitoring (every 2-4 hours) is essential to ensure the 24-hour correction does not exceed 8 mEq/L.

Step-by-Step Solution

1
Recognize the clinical emergency and administer hypertonic saline.
Increases serum osmolarity and draws water out of brain cells to lower intracranial pressure.
The patient's active seizures and profound hyponatremia (114 mEq/L) indicate severe cerebral edema requiring immediate intervention.
2
Recheck the serum sodium level and patient symptoms rapidly after the first intervention.
Confirms whether the acute goal (a 4-6 mEq/L increase) has been met or if an additional bolus is needed.
Without prompt monitoring, the clinician cannot gauge the effectiveness of the initial life-saving therapy.
3
Stop the hypertonic saline infusion as soon as critical symptoms resolve.
Halts the rapid rise in serum sodium.
Prolonging hypertonic saline after symptoms have cleared unnecessarily risks iatrogenic overcorrection.
4
Institute serial sodium monitoring every 2 to 4 hours.
Maintains the total sodium correction within the safe threshold (maximum 8 mEq/L per 24 hours).
Vigilant evaluation during the maintenance phase is essential to prevent osmotic demyelination syndrome.

Key Concept

Management of severe symptomatic hyponatremia requires rapid initial correction with hypertonic saline, guided by frequent monitoring, followed by prompt de-escalation and strict limits on the 24-hour correction rate.
Estimated Time:1m 30s
Question 1946Question →

A 68-year-old woman is brought to the emergency department by her family due to progressive confusion, fever, and severe right upper quadrant abdominal pain that began 24 hours ago. On presentation, her temperature is 39.2∘C39.2^\circ\text{C} (102.6∘F102.6^\circ\text{F}), blood pressure is 82/50 mmHg82/50\text{ mmHg}, pulse is 124/min124/\text{min}, and respiratory rate is 22/min22/\text{min}. Physical examination reveals scleral icterus, severe right upper quadrant tenderness with involuntary guarding, and lethargy. Laboratory studies show a leukocyte count of 18,500/mm318,500/\text{mm}^3, total bilirubin of 6.2 mg/dL6.2\text{ mg/dL}, direct bilirubin of 4.8 mg/dL4.8\text{ mg/dL}, and alkaline phosphatase of 450 U/L450\text{ U/L}. A bedside right upper quadrant ultrasound demonstrates a dilated common bile duct measuring 12 mm12\text{ mm} and gallstones within the gallbladder. Arrange the following management steps in the most appropriate chronological sequence for this patient.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct chronological sequence is to first administer an intravenous crystalloid fluid bolus, followed by broad-spectrum intravenous antibiotics, then perform an urgent endoscopic retrograde cholangiopancreatography (ERCP), and finally perform a laparoscopic cholecystectomy at a later date.
The patient's presentation of fever, right upper quadrant pain, jaundice, hypotension, and altered mental status represents Reynolds pentad, which is pathognomonic for acute suppurative cholangitis with septic shock. The foundational sequence for surgical and procedural emergencies is to first medically stabilize the patient (IV fluids), medically treat the underlying pathology (IV antibiotics), perform minimally invasive source control (urgent ERCP), and reserve definitive high-risk surgery (cholecystectomy) for when the patient has recovered.

Step-by-Step Solution

1
Administer intravenous crystalloid fluid bolus
Restores intravascular volume and improves mean arterial pressure.
The patient is presenting with Reynolds pentad (fever, jaundice, RUQ pain, hypotension, altered mental status) indicative of acute suppurative cholangitis complicated by septic shock. The universal first step in shock management is ABCs and volume resuscitation.
2
Administer broad-spectrum intravenous antibiotics
Initiates systemic treatment of the biliary infection.
In sepsis, antibiotics must be administered as soon as possible after recognizing shock and obtaining blood cultures, ideally within the first hour of presentation.
3
Perform urgent endoscopic retrograde cholangiopancreatography (ERCP)
Decompresses the obstructed, infected biliary tree.
While antibiotics suppress the systemic infection, source control is mandatory. ERCP with sphincterotomy and stone extraction (or stent placement) is the procedure of choice for decompression, but it must be performed after initial hemodynamic stabilization.
4
Perform laparoscopic cholecystectomy
Removes the source of the gallstones, preventing future episodes.
Definitive surgical management is necessary but poses an unacceptably high mortality risk if performed during acute septic shock. It is done electively after the patient has recovered.

Key Concept

The management of acute cholangitis with septic shock requires strict sequencing: immediate hemodynamic resuscitation, broad-spectrum antibiotics, urgent biliary decompression (e.g., ERCP), and delayed definitive surgery (cholecystectomy).
Question 1947Question →

For each patient presenting to the primary care clinic, select the single most appropriate, guideline-concordant preventive care intervention from the available choices.

Click a left item, then click its matching right item

Items

A 38-year-old man with a BMI of 31 kg/m² and blood pressure of 128/80 mmHg who has not been evaluated by a physician in 5 years.
A 48-year-old woman with no notable medical or family history who is presenting for an initial wellness examination and has never undergone malignancy screening.
A 55-year-old man with chronic obstructive pulmonary disease and active tobacco use who received an annual influenza vaccination last week.
A 24-year-old healthy man presenting for an administrative physical who reports consuming 5 to 6 alcoholic beverages per occasion on most weekends.

Matches

Show answer & explanation

Answer

The 38-year-old man requires diabetes screening due to his age and BMI. The 48-year-old woman requires colorectal cancer screening, which begins at age 45. The 55-year-old man with COPD requires the pneumococcal conjugate vaccine due to his high-risk comorbidities. The 24-year-old man requires alcohol misuse screening and counseling due to his binge drinking behavior.
Each patient's clinical profile directly aligns with an established grade A or B recommendation from the USPSTF or an ACIP adult immunization guideline. The 38-year-old meets the age and BMI criteria for diabetes screening; the 48-year-old requires routine colorectal cancer screening initiated at 45; the 55-year-old has COPD and smokes, warranting pneumococcal vaccination before 65; and the 24-year-old's binge drinking requires behavioral counseling.

Step-by-Step Solution

1
Evaluate the 38-year-old man's risk factors based on his age (38) and BMI (31 kg/m²).
He meets the criteria for metabolic screening.
Current USPSTF guidelines mandate type 2 diabetes screening starting at age 35 for individuals with a BMI greater than or equal to 25 kg/m².
2
Assess the 48-year-old woman's need for age-based cancer screening, noting she has never been screened.
She requires colorectal cancer screening.
The threshold for average-risk colorectal cancer screening is age 45, making this her priority intervention.
3
Identify indicated vaccines for the 55-year-old man with COPD and a history of smoking.
He requires the pneumococcal conjugate vaccine.
While routine pneumococcal vaccination begins at age 65, chronic lung disease and smoking are high-risk conditions warranting early immunization between ages 19 and 64.
4
Determine behavioral counseling needs for the 24-year-old man reporting 5 to 6 drinks per occasion.
He requires alcohol misuse screening and brief counseling.
Consuming 5 or more alcoholic beverages on a single occasion constitutes binge drinking for men, fulfilling the criteria for brief behavioral intervention.

Key Concept

Applying current age- and risk-based USPSTF and ACIP preventive care guidelines to diverse adult ambulatory populations.
Question 1948Question →

A 62-year-old female presents to the emergency department complaining of severe, crushing substernal chest pain radiating to her left arm, which started 22 hours ago while resting. She also reports progressive shortness of breath over the same period. Her past medical history is significant for hypertension, type 2 diabetes mellitus, and hyperlipidemia. Vital signs show a blood pressure of 155/92155/92 mmHg, heart rate of 112112/min, respiratory rate of 2424/min, and oxygen saturation of 89%89\% on room air. Physical examination reveals prominent jugular venous distention. Cardiac auscultation reveals an S3 gallop, and pulmonary auscultation demonstrates bilateral crackles extending to the mid-lung fields. An electrocardiogram shows 22 mm ST-segment depressions in leads V2-V5 and T-wave inversions in leads I and aVL. There are no ST-segment elevations. Laboratory studies reveal a markedly elevated high-sensitivity cardiac troponin T. In addition to supplemental oxygen and sublingual nitroglycerin, which of the following pharmacologic interventions should be ordered for this patient at this time? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Chewable aspirin 325 mg; Intravenous unfractionated heparin; High-intensity oral atorvastatin

Answer

The correct pharmacologic interventions to order immediately are chewable aspirin, intravenous unfractionated heparin, and high-intensity oral atorvastatin.
This patient is presenting with a Non-ST-Elevation Myocardial Infarction (NSTEMI) complicated by acute decompensated heart failure. The standard of care for early management of NSTEMI includes dual antiplatelet therapy (starting immediately with aspirin), therapeutic anticoagulation (such as unfractionated heparin) to prevent further thrombus formation, and a high-intensity statin (such as atorvastatin) for its pleiotropic plaque-stabilizing effects. These three interventions are indicated universally in NSTEMI unless specific absolute contraindications exist, none of which are present for these three drugs in this patient.

Step-by-Step Solution

1
Interpret the clinical presentation, electrocardiogram, and laboratory results.
The patient's ischemic chest pain, elevated cardiac troponin, and ST-segment depressions in the absence of ST elevations indicate a diagnosis of Non-ST-Elevation Myocardial Infarction (NSTEMI).
Establishing the precise type of acute coronary syndrome is necessary to activate the correct evidence-based treatment protocol.
2
Assess the patient's hemodynamic status and physical examination findings for concurrent complications.
The presence of severe hypoxia, an S3 gallop, jugular venous distention, and extensive pulmonary crackles firmly establishes a concurrent diagnosis of acute decompensated heart failure.
Identifying acute heart failure is critical because it fundamentally alters the safety profile of standard acute coronary syndrome medications.
3
Determine the appropriate combination of early pharmacologic interventions while avoiding contraindicated agents.
Standard NSTEMI therapy requires antiplatelet agents (aspirin), anticoagulation (heparin), and plaque stabilization (atorvastatin). Beta-blockers must be withheld due to the acute decompensated heart failure. Fibrinolytics must be withheld because they are contraindicated in NSTEMI.
Selecting the correct multi-drug regimen requires balancing the need to treat the acute ischemic event against the risk of worsening the patient's acute cardiogenic pulmonary edema and avoiding interventions known to cause harm in non-ST-elevation events.

Key Concept

Pharmacologic management of NSTEMI complicated by acute decompensated heart failure
Question 1949Question →

A 5858-year-old man is evaluated in the hospital for worsening renal function. He was admitted 33 days ago for fever, confusion, and abdominal pain. He has a history of alcohol-associated cirrhosis. On admission, diagnostic paracentesis revealed an ascitic fluid absolute neutrophil count of 600/mm3600/\text{mm}^3. He was appropriately started on intravenous cefotaxime, and his home regimen of spironolactone and furosemide was discontinued.

Despite resolving fever and improving mental status over the past 4848 hours, his urine output has decreased to 300300 mL/day. Vital signs today show a temperature of 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure of 88/5288/52 mmHg, and heart rate of 94/min94/\text{min}. Physical examination reveals scleral icterus, spider angiomas, and tense ascites without peripheral edema.

Laboratory results:
Sodium: 130130 mEq/L
Potassium: 4.84.8 mEq/L
Blood urea nitrogen: 6868 mg/dL (was 2222 mg/dL on admission)
Creatinine: 3.23.2 mg/dL (was 1.11.1 mg/dL on admission)
Urine sodium: 88 mEq/L
Urinalysis: No red blood cells, white blood cells, or casts.

A volume expansion trial with intravenous albumin (11 g/kg/day for 22 days) was completed, but his repeat serum creatinine today is 3.43.4 mg/dL. Renal ultrasound reveals normal-sized kidneys with no hydronephrosis.

Which of the following is the most appropriate next pharmacologic intervention for this patient's renal failure?

Show answer & explanation

Answer: Intravenous terlipressin

Answer

Intravenous terlipressin
The correct answer is a splanchnic vasoconstrictor. The patient's clinical presentation of progressive acute kidney injury in the setting of decompensated cirrhosis, oliguria, very low urine sodium, absence of intrinsic renal disease, and failure to improve after a 4848-hour albumin challenge confirms the diagnosis of hepatorenal syndrome-acute kidney injury (HRS-AKI). The fundamental pathophysiology of HRS is severe splanchnic arterial vasodilation, which triggers compensatory but deleterious intense renal vasoconstriction. The most appropriate pharmacologic intervention is a splanchnic vasoconstrictor, such as intravenous terlipressin, alongside continued albumin administration. Terlipressin counteracts the splanchnic vasodilation, improving effective arterial blood volume and restoring renal perfusion.

Step-by-Step Solution

1
Analyze the patient's clinical and laboratory trajectory.
The patient has advanced cirrhosis and developed severe acute kidney injury (creatinine from 1.1 to 3.4 mg/dL) with oliguria and profound sodium retention (urine sodium < 10 mEq/L).
Tracking renal function changes identifies the severity and phenotype of the acute kidney injury.
2
Rule out intrinsic and post-renal causes of acute kidney injury.
Urinalysis is bland (no casts or cells) and renal ultrasound is normal, ruling out acute tubular necrosis and obstructive uropathy.
Establishing a pre-renal or functional etiology is required before diagnosing hepatorenal syndrome.
3
Evaluate the response to fluid resuscitation.
The patient failed to improve after a 48-hour challenge with intravenous albumin.
Failure to respond to albumin withdrawal confirms the diagnosis of Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI).
4
Determine the appropriate pharmacologic mechanism to reverse HRS-AKI.
Select a splanchnic vasoconstrictor to counteract the profound splanchnic vasodilation driving the syndrome.
Intravenous terlipressin (often in combination with albumin) is the standard-of-care pharmacologic intervention to restore effective arterial blood volume and renal perfusion.

Key Concept

Diagnosis and pharmacologic management of Hepatorenal Syndrome (HRS-AKI) using splanchnic vasoconstrictors.
Question 1950Question →

A hematology consultation is requested for a 61-year-old man hospitalized with a massive left popliteal deep vein thrombosis. He was initially managed with a continuous intravenous infusion of unfractionated heparin. On hospital day 6, his platelet count fell precipitously from an admission baseline of 260,000/μL260,000/\mu L to 75,000/μL75,000/\mu L. Suspecting a drug-induced complication, the medical team obtained a serotonin release assay, which returned positive. All heparin products were immediately withdrawn, and an intravenous argatroban infusion was initiated. Now, on hospital day 10, the patient's lower extremity edema has significantly improved, and his platelet count has steadily recovered to 155,000/μL155,000/\mu L. The clinical team is preparing for discharge and plans to transition his antithrombotic therapy to oral warfarin. Which of the following outlines the most appropriate strategy for monitoring and adapting his pharmacotherapy?

Show answer & explanation

Answer: Initiate warfarin, continue the argatroban infusion for at least five days, and discontinue argatroban only when the international normalized ratio is greater than 4.04.0.

Answer

The most appropriate strategy is to initiate warfarin, overlap it with the argatroban infusion for a minimum of 5 days, and discontinue argatroban only when the international normalized ratio exceeds 4.0.
This strategy correctly addresses both the pathophysiology of heparin-induced thrombocytopenia (HIT) and the laboratory artifacts caused by direct thrombin inhibitors (DTIs). Warfarin should only be initiated after platelets recover to at least 150,000/μL150,000/\mu L, which this patient has successfully achieved. Because warfarin causes an initial precipitous decline in Protein C before fully depleting procoagulant factors, patients experience a transient hypercoagulable state. Therefore, warfarin must be overlapped with a non-heparin parenteral anticoagulant (argatroban) for a minimum of 5 days. Crucially, argatroban falsely prolongs the prothrombin time (PT) and international normalized ratio (INR). If argatroban is stopped when the combined INR reaches the standard 2.0−3.02.0-3.0 range, the true warfarin-only INR will plummet to subtherapeutic levels once the DTI clears. Current clinical guidelines mandate targeting a combined INR of >4.0> 4.0 before terminating argatroban to ensure the true, underlying INR remains therapeutic.

Step-by-Step Solution

1
Identify the primary clinical challenge and the current phase of treatment.
The patient has confirmed heparin-induced thrombocytopenia (HIT) and is recovering on argatroban (a direct thrombin inhibitor).
Recognizing the current phase of HIT treatment dictates the strict protocols for transitioning to oral anticoagulation safely.
2
Determine the prerequisite for initiating a vitamin K antagonist in a patient with HIT.
Warfarin can be safely started because the patient's platelet count has recovered to over 150,000/μL150,000/\mu L.
Starting warfarin during profound thrombocytopenia in HIT significantly increases the risk of venous limb gangrene and skin necrosis.
3
Evaluate the pharmacokinetic interaction between argatroban and PT/INR laboratory testing.
Argatroban artificially prolongs the prothrombin time, leading to a falsely elevated INR reading.
Direct thrombin inhibitors interfere with standard coagulation assays, necessitating altered therapeutic targets during the overlap phase.
4
Select the correct monitoring parameters for the transition protocol.
Overlap therapy for at least 5 days and until the combined INR is >4.0> 4.0.
An INR >4.0> 4.0 on combined therapy ensures that when argatroban is stopped, the true warfarin-induced INR will remain in the therapeutic range of 2.02.0 to 3.03.0.

Key Concept

Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia requires a minimum 5-day overlap and a target combined INR of > 4.0 due to argatroban's artifactual prolongation of the prothrombin time.
Estimated Time:2m 0s
Question 1951Question →

A 6868-year-old man presents to the clinic for a routine diabetes follow-up. He has a 1212-year history of type 2 diabetes mellitus, hypertension, and hyperlipidemia. His current medications include metformin 1000 mg1000\text{ mg} twice daily, amlodipine 5 mg5\text{ mg} daily, atorvastatin 40 mg40\text{ mg} daily, and aspirin 81 mg81\text{ mg} daily. He feels well and reports no polyuria, polydipsia, or peripheral edema.

Vital signs are temperature 37.0∘C37.0^\circ\text{C} (98.6∘F98.6^\circ\text{F}), blood pressure 132/80 mmHg132/80\text{ mmHg}, and heart rate 72/min72/\text{min}. Physical examination reveals diminished vibratory sensation in both feet but is otherwise unremarkable.

Laboratory results are as follows:

TestResult
Hemoglobin A1c7.1%7.1\%
Serum sodium139 mEq/L139\text{ mEq/L}
Serum potassium4.4 mEq/L4.4\text{ mEq/L}
Serum creatinine1.7 mg/dL1.7\text{ mg/dL} (baseline 1.2 mg/dL1.2\text{ mg/dL} two years ago)
Estimated GFR42 mL/min/1.73 m242\text{ mL/min/1.73 m}^2

Urinalysis shows microalbuminuria but no hematuria or cellular casts.

Based on the laboratory findings, which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

Show answer & explanation

Answer: Reduce the metformin dosage to 500 mg500\text{ mg} twice daily and recheck renal function in 33 months.

Answer

Reduce the metformin dosage to 500 mg500\text{ mg} twice daily and recheck renal function in 33 months.
The correct action is to reduce the metformin dosage by half and monitor renal function closely. Metformin is excreted unchanged in the urine, and impaired renal function causes the drug to accumulate, which inhibits hepatic gluconeogenesis and mitochondrial respiration, increasing the risk of lactic acidosis. According to current guidelines, metformin does not need to be discontinued unless the eGFR falls below 30 mL/min/1.73 m230\text{ mL/min/1.73 m}^2. However, when the eGFR is between 3030 and 45 mL/min/1.73 m245\text{ mL/min/1.73 m}^2 (as in this patient with an eGFR of 4242), the maximum recommended daily dose is 1000 mg1000\text{ mg}, and renal function should be monitored every 33 to 66 months.

Step-by-Step Solution

1
Evaluate the patient's current renal function against historical baseline.
The eGFR has declined from a normal baseline to 42 mL/min/1.73 m242\text{ mL/min/1.73 m}^2, indicating the progression to stage 3b chronic kidney disease (CKD).
Recognizing the current stage of CKD is necessary to evaluate the safety and dosing of renally cleared medications.
2
Review the patient's medication list for drugs requiring dose adjustment based on the new eGFR.
The patient is taking metformin 1000 mg1000\text{ mg} twice daily (total 2000 mg/day2000\text{ mg/day}).
Metformin can accumulate in renal impairment, leading to a rare but life-threatening complication known as metformin-associated lactic acidosis.
3
Apply evidence-based guidelines for metformin use in CKD.
Guidelines recommend that if eGFR falls to 30−45 mL/min/1.73 m230-45\text{ mL/min/1.73 m}^2, the dose should be reduced by 50%50\% (maximum 1000 mg/day1000\text{ mg/day}) and renal function monitored every 33 to 66 months. It is only absolutely contraindicated if eGFR is <30 mL/min/1.73 m2< 30\text{ mL/min/1.73 m}^2.
Ensures the patient continues to receive the insulin-sensitizing benefits of metformin while minimizing the risk of toxicity.

Key Concept

Metformin requires dose adjustment (maximum 1000 mg/day1000\text{ mg/day}) and closer monitoring when the estimated glomerular filtration rate (eGFR) falls between 3030 and 45 mL/min/1.73 m245\text{ mL/min/1.73 m}^2, and it must be discontinued entirely if the eGFR falls below 30 mL/min/1.73 m230\text{ mL/min/1.73 m}^2.
Estimated Time:1m 0s
Question 1952Question →

A 72-year-old man comes to the clinic for a routine health maintenance examination. His medical history includes type 2 diabetes mellitus, hypertension, and hyperlipidemia. He does not use tobacco. Current medications are metformin, lisinopril, and atorvastatin. He has no history of myocardial infarction, angina, stroke, or transient ischemic attack. Vital signs include a blood pressure of 132/80 mmHg and a heart rate of 74/min. Physical examination is unremarkable. His most recent hemoglobin A1c is 7.2%. The patient recently read an article about cardiovascular health and asks if he should start taking a daily low-dose aspirin to prevent a heart attack. According to current preventive care guidelines, which of the following is the most appropriate recommendation regarding aspirin therapy for this patient?

Show answer & explanation

Answer: Advise against initiating daily aspirin therapy.

Answer

The most appropriate recommendation is to advise against initiating daily aspirin therapy because the risk of bleeding in this age group outweighs the cardiovascular benefits for primary prevention.
The most appropriate action is to advise against initiating low-dose aspirin therapy. This patient requires primary prevention, as he has no history of established atherosclerotic cardiovascular disease (ASCVD). The United States Preventive Services Task Force (USPSTF) recommends against initiating low-dose aspirin for the primary prevention of CVD in adults 60 years or older (Grade D recommendation). Similarly, the American College of Cardiology/American Heart Association (ACC/AHA) guidelines state that aspirin should not be administered on a routine basis for primary prevention in adults over 70 years of age. In older adults, the risk of severe bleeding (gastrointestinal and intracranial) outweighs any small potential benefit in reducing cardiovascular events. Although he has diabetes, statin and blood pressure management are the preferred interventions for cardiovascular risk reduction in this scenario.

Step-by-Step Solution

1
Determine if the scenario involves primary or secondary cardiovascular prevention.
The patient has no history of myocardial infarction, stroke, or angina, establishing this as primary prevention.
Aspirin guidelines differ drastically between primary prevention (preventing a first event) and secondary prevention (preventing a subsequent event).
2
Identify the patient's age and apply current primary prevention guidelines.
The patient is 72 years old. Current major guidelines recommend against initiating aspirin for primary prevention in this age group.
The United States Preventive Services Task Force (USPSTF) recommends against initiating low-dose aspirin in adults 60 years or older (Grade D), and the ACC/AHA guidelines strongly recommend against it for adults over 70.
3
Evaluate if the patient's comorbidities override the age-based recommendation.
Despite having diabetes, hypertension, and hyperlipidemia, the risk of gastrointestinal and intracranial bleeding at age 72 outweighs the potential cardiovascular benefits of new aspirin initiation.
Age is the strongest predictor of bleeding risk on aspirin therapy, which negates the absolute risk reduction of cardiovascular events in older adults without established disease.

Key Concept

Initiation of aspirin for primary prevention of cardiovascular disease is not recommended in older adults (≥60 years per USPSTF, >70 years per ACC/AHA) due to the increased risk of bleeding outweighing the benefits.
Estimated Time:1m 30s
Question 1953Question →

A 42-year-old woman is evaluated in the clinic for severe, seropositive rheumatoid arthritis that remains highly active despite six months of maximally tolerated methotrexate and folic acid therapy. The physician plans to add adalimumab to her current regimen. She has a past medical history of mild intermittent asthma. Current medications include methotrexate, folic acid, and an as-needed albuterol inhaler. Vital signs are within normal limits. Physical examination reveals active synovitis with swelling and tenderness in the bilateral metacarpophalangeal and proximal interphalangeal joints. Which of the following baseline and ongoing monitoring parameters are required for this patient's new pharmacological regimen? (Select 3)

Select all that apply

Show answer & explanation

Answer: Baseline interferon-gamma release assay (IGRA) or tuberculin skin test; Baseline screening for hepatitis B surface antigen and core antibody; Periodic evaluation of complete blood count, serum creatinine, and liver transaminases

Answer

The required monitoring parameters include baseline tuberculosis screening (IGRA or TST), baseline hepatitis B serologic screening, and periodic monitoring of CBC, renal function, and liver transaminases.
The correct parameters encompass the mandatory baseline infectious disease screening for TNF-alpha inhibitors and the standard ongoing toxicity monitoring for methotrexate. Adalimumab, like all TNF-alpha inhibitors, disrupts granuloma formation and macrophage function, carrying a black box warning for the reactivation of latent tuberculosis and hepatitis B. Therefore, screening with an interferon-gamma release assay (or tuberculin skin test) and hepatitis B serologies (HBsAg, anti-HBc) is universally required before initiation. Concurrently, the patient is continuing methotrexate, which inhibits dihydrofolate reductase and can cause myelosuppression, hepatotoxicity, and renal impairment. Clinical guidelines mandate periodic monitoring of complete blood count, liver transaminases, and serum creatinine to detect early, asymptomatic organ toxicity.

Step-by-Step Solution

1
Identify the proposed pharmacological regimen and associated high-yield toxicities.
The patient will be taking methotrexate (risk of myelosuppression, hepatotoxicity, renal dysfunction) and adalimumab, a TNF-alpha inhibitor (risk of opportunistic infections, particularly granulomatous and viral).
Recognizing the specific adverse effect profiles of these disease-modifying antirheumatic drugs (DMARDs) dictates the monitoring strategy.
2
Determine the baseline screening requirements for initiating a TNF-alpha inhibitor.
Baseline screening for latent tuberculosis (via IGRA or TST) and hepatitis B (HBsAg and anti-HBc) must be performed.
TNF-alpha is essential for macrophage function and granuloma maintenance. Inhibition can lead to rapid, disseminated reactivation of latent TB and severe reactivation of hepatitis B.
3
Determine the ongoing laboratory monitoring requirements for methotrexate.
Routine periodic evaluation of complete blood count, serum creatinine, and liver transaminases is required.
Methotrexate is an antimetabolite that can cause dose-dependent toxicities requiring routine surveillance to ensure safety and allow for dose adjustments.
4
Evaluate the necessity of cardiac or autoimmune screening based on the medication profile.
Baseline echocardiography and routine ANA screening are not indicated for this asymptomatic patient.
While TNF inhibitors are contraindicated in severe heart failure and can rarely cause drug-induced lupus, clinical guidelines do not support routine baseline echocardiograms or serial autoantibody screening in asymptomatic individuals without a suggestive history.

Key Concept

Prior to initiating TNF-alpha inhibitors, patients must be screened for latent tuberculosis and hepatitis B. Patients on methotrexate require ongoing monitoring of complete blood count, liver transaminases, and renal function.
Question 1954Question →

A 71-year-old woman is evaluated via telehealth for dysuria, suprapubic discomfort, and urinary urgency that began 2 days ago. She has a history of a mechanical mitral valve replacement performed 3 years ago, for which she takes chronic warfarin. Her most recent international normalized ratio (INR) checked one week ago was 2.9, which is within her target range of 2.5 to 3.5. She reports no fever, chills, back pain, or gross hematuria. A clean-catch urinalysis obtained at a local laboratory demonstrates positive nitrites, positive leukocyte esterase, and >50 white blood cells per high-power field. The physician diagnoses acute uncomplicated cystitis and plans to prescribe a 3-day course of trimethoprim-sulfamethoxazole.

Which of the following are necessary monitoring and treatment adjustments for this patient? (Select 2 options)

Select all that apply

Show answer & explanation

Answer: Preemptively reduce the weekly warfarin dose by 25% to 50%; Schedule a repeat international normalized ratio (INR) measurement in 3 to 5 days

Answer

Preemptively reduce the weekly warfarin dose by 25% to 50% AND schedule a repeat international normalized ratio (INR) measurement in 3 to 5 days.
Trimethoprim-sulfamethoxazole (TMP-SMX) strongly interacts with warfarin, primarily through the inhibition of the cytochrome P450 2C9 (CYP2C9) enzyme. CYP2C9 is responsible for metabolizing the more potent S-enantiomer of warfarin. Additionally, broad-spectrum antibiotics like TMP-SMX eradicate intestinal flora that produce vitamin K, further enhancing the anticoagulant effect. This synergistic interaction predictably leads to a rapid and clinically significant elevation of the INR, increasing the risk of life-threatening hemorrhage. To safely manage this interaction when concurrent use is unavoidable, the standard of care requires a preemptive reduction of the weekly warfarin dose by 25% to 50%. Because the INR can spike within days of starting the antibiotic, close monitoring is mandatory; checking a repeat INR within 3 to 5 days allows for timely detection of over-anticoagulation and further dose adjustments if necessary.

Step-by-Step Solution

1
Identify the primary pharmacological interaction.
Trimethoprim-sulfamethoxazole inhibits CYP2C9 and depletes vitamin K-producing gut flora, significantly increasing warfarin's anticoagulant effect.
Recognizing drug-drug interactions is critical before prescribing new medications to patients on chronic narrow-therapeutic-index drugs.
2
Determine the necessary dose adjustment.
Reduce the weekly warfarin dose by 25% to 50%.
Preemptive dose reduction mitigates the anticipated supratherapeutic spike in INR and prevents severe bleeding events.
3
Establish the appropriate monitoring interval.
Check the INR within 3 to 5 days of initiating the antibiotic.
The onset of the interaction is rapid; early monitoring allows for further titration before dangerous coagulopathy develops.

Key Concept

Patients stabilized on warfarin who are prescribed highly interacting antibiotics (such as trimethoprim-sulfamethoxazole) require preemptive dose reductions (typically 25% to 50%) and early follow-up INR monitoring (within 3 to 5 days) to prevent life-threatening hemorrhage.
Question 1955Question →

A 28-year-old woman is brought to the emergency department after being stung by a bee while hiking. She is profusely sweating and reports difficulty breathing along with a feeling of impending doom. On physical examination, she has diffuse coalescing urticaria, marked facial angioedema, and audible biphasic wheezing. Her blood pressure is 78/4078/40 mmHg, heart rate is 135135/min, and oxygen saturation is 88%88\% on room air. Large-bore intravenous access is rapidly established.

Assuming her hemodynamic instability and symptoms persist despite each successive intervention, arrange the following pharmacologic therapies in the correct sequential order of administration according to anaphylaxis resuscitation guidelines.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence prioritizes immediate life-saving interventions over delayed adjunctive therapies: first, administer intramuscular epinephrine; second, provide a rapid intravenous normal saline bolus; third, initiate an intravenous epinephrine continuous infusion; and finally, administer intravenous methylprednisolone.
The correct sequence follows the standard critical care algorithm for anaphylaxis: absolute priority is given to reversing immediate life-threats with intramuscular epinephrine, followed by aggressive fluid resuscitation for distributive shock. Escalation to an intravenous vasopressor drip is reserved for refractory shock, and adjunctive medications with delayed onsets of action (like corticosteroids) are administered last, ensuring acute resuscitation is not delayed.

Step-by-Step Solution

1
Recognize the clinical presentation of anaphylactic shock.
The patient has severe anaphylaxis with airway compromise and distributive shock.
Immediate recognition is required to initiate a tiered, time-sensitive resuscitation protocol.
2
Administer the definitive first-line therapy.
Intramuscular epinephrine is administered into the anterolateral thigh.
Epinephrine is the only medication that prevents death in anaphylaxis by reversing airway edema and cardiovascular collapse. It must precede all other treatments.
3
Address persistent distributive shock.
A rapid intravenous normal saline bolus is given.
Anaphylaxis causes profound third-spacing and vasodilation. Massive fluid resuscitation is necessary when intramuscular epinephrine alone fails to restore blood pressure.
4
Manage refractory cardiovascular collapse.
An intravenous epinephrine continuous infusion is initiated.
When adequate volume loading and repeated intramuscular epinephrine doses fail, an intravenous vasopressor infusion is required to maintain organ perfusion.
5
Provide adjunctive medical therapy.
Intravenous methylprednisolone is administered.
Glucocorticoids help mitigate prolonged or biphasic anaphylactic reactions. Due to their delayed onset (hours), they must only be given after the patient is hemodynamically stabilized.

Key Concept

Prioritization of hemodynamic stabilization in refractory anaphylaxis
Question 1956Question →

While recovering in the intensive care unit from a severe exacerbation of chronic obstructive pulmonary disease requiring mechanical ventilation, a 74-year-old male develops a new-onset fever of 38.9°C (102.0°F) and increasing vasopressor requirements. His medical history includes coronary artery disease, chronic obstructive pulmonary disease, and heart failure with preserved ejection fraction. Physical examination reveals a distended abdomen with focal guarding in the right upper quadrant. Laboratory studies show a leukocyte count of 18,500/mm³ and mild elevations in aspartate aminotransferase and alanine aminotransferase, with a normal total bilirubin level. A bedside right upper quadrant ultrasound demonstrates gallbladder wall thickening to 6 mm, pericholecystic fluid, and a sonographic Murphy sign, without intrahepatic or extrahepatic biliary ductal dilation. Which of the following is the most appropriate procedural intervention for this patient's current abdominal condition?

Show answer & explanation

Answer: Placement of a percutaneous cholecystostomy tube

Answer

Placement of a percutaneous cholecystostomy tube is the correct intervention for this hemodynamically unstable patient with acute cholecystitis.
The correct answer is placement of a percutaneous cholecystostomy tube. This patient is suffering from acute cholecystitis, which is driving his septic shock. While the definitive treatment for acute cholecystitis is a laparoscopic cholecystectomy, this patient is critically ill (mechanically ventilated, requiring vasopressors) and is a prohibitive surgical risk. In such high-risk patients, a percutaneous cholecystostomy tube placed under image guidance allows for decompression and drainage of the infected gallbladder, providing adequate source control while avoiding the physiological stress of general anesthesia and surgery. Once the patient recovers from the acute illness, a delayed cholecystectomy can be reconsidered.

Step-by-Step Solution

1
Identify the primary diagnosis based on clinical and radiographic findings.
The patient has acute cholecystitis, evidenced by right upper quadrant guarding, fever, leukocytosis, and characteristic ultrasound findings (thickened gallbladder wall, pericholecystic fluid).
Establishing the acute intra-abdominal process is necessary to target therapy.
2
Assess the patient's surgical risk and hemodynamic status.
The patient is on mechanical ventilation, requires increasing vasopressors, and has severe cardiopulmonary comorbidities, classifying him as critically ill and a prohibitively high-risk surgical candidate.
Surgical risk stratification determines whether the patient can safely undergo definitive operative management (cholecystectomy).
3
Select the most appropriate therapeutic intervention for a poor surgical candidate.
Determine that percutaneous cholecystostomy provides necessary source control for the infected gallbladder without the risks associated with general anesthesia and surgery.
Drainage of the infected source is mandated in sepsis, but must be balanced against the patient's ability to tolerate the procedure.

Key Concept

Percutaneous cholecystostomy is the preferred initial procedural intervention for acute cholecystitis in critically ill patients who are hemodynamically unstable or otherwise poor candidates for surgery.
Estimated Time:1m 15s
Question 1957Question →

A 54-year-old woman comes to the clinic for a routine health maintenance examination. She feels well and has no acute complaints. Her medical history is significant for hypertension and stage 3a chronic kidney disease secondary to hypertensive nephrosclerosis. Her current medications include lisinopril and amlodipine. She smoked 1 pack of cigarettes daily for 25 years but successfully quit 10 years ago. Her most recent screening colonoscopy was performed 9 years ago and revealed no polyps. She underwent a screening mammogram 1 year ago, which was normal. She received the two-dose recombinant zoster vaccine series 2 years ago, the annual influenza vaccine last month, and a Tdap booster 3 years ago. She has not received any other immunizations in adulthood. Vital signs are within normal limits. Physical examination is unremarkable. Which of the following interventions are indicated for this patient today? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: 20-valent pneumococcal conjugate vaccine (PCV20); Low-dose computed tomography (LDCT) of the chest

Answer

The indicated interventions for this patient are the 20-valent pneumococcal conjugate vaccine (PCV20) and low-dose computed tomography (LDCT) of the chest.
The correct interventions are the 20-valent pneumococcal conjugate vaccine (PCV20) and low-dose computed tomography (LDCT) of the chest. According to the Advisory Committee on Immunization Practices (ACIP), adults aged 19 to 64 years with specific underlying medical conditions, including chronic kidney disease (CKD), should receive pneumococcal vaccination. As this patient is vaccine-naive for pneumococcus, a single dose of PCV20 (or PCV15 followed by PPSV23) is indicated. Furthermore, the US Preventive Services Task Force (USPSTF) recommends annual lung cancer screening with LDCT for adults aged 50 to 80 years who have a 20 pack-year or greater smoking history and currently smoke or have quit within the past 15 years. This 54-year-old patient has a 25 pack-year history and quit 10 years ago, making her eligible.

Step-by-Step Solution

1
Evaluate the patient's vaccination requirements based on her age and medical history.
Because she has stage 3a chronic kidney disease, she meets criteria for pneumococcal vaccination before age 65.
The ACIP recommends pneumococcal vaccination for adults aged 19-64 with specific risk factors, including chronic kidney disease.
2
Assess the patient's eligibility for lung cancer screening.
She is 54 years old, has a 25 pack-year smoking history, and quit 10 years ago, meeting all criteria for LDCT.
The USPSTF recommends annual LDCT for adults aged 50 to 80 years with a ≥20 pack-year history who smoke or quit within the last 15 years.
3
Review the intervals for her previously completed cancer screenings.
Her last colonoscopy was 9 years ago (due in 1 year) and her last mammogram was 1 year ago (due in 1 year).
Guidelines recommend colonoscopy every 10 years and mammography every 2 years for average-risk adults.

Key Concept

Application of condition-specific adult immunization guidelines and interval-based cancer screening protocols.

Alternative Method

When evaluating complex preventive care vignettes, systematically separate interventions into three categories: Age-based, Risk/Exposure-based, and Interval-based to ensure no overlapping criteria are missed.
Estimated Time:1m 30s
Question 1958Question →

A 24-year-old man is evaluated in the emergency department for severe right lower leg pain. Two hours ago, he sustained a closed mid-shaft tibial fracture during a soccer game and was subsequently placed in a circumferential long-leg cast. He now reports excruciating, throbbing pain in the right leg that is rapidly worsening and completely unrelieved by intravenous morphine. Vital signs are temperature 37.1°C (98.8°F), blood pressure 138/86 mm Hg, heart rate 112/min, and respiratory rate 18/min. On examination, the leg feels intensely tight, and passive extension of the toes elicits agonizing pain. Paresthesias are noted over the dorsum of the foot. Distal dorsalis pedis and posterior tibial pulses are palpable. What is the most appropriate sequential order of management steps for this patient?

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for managing suspected acute compartment syndrome is to first relieve external compression by removing the cast, then objectively measure tissue pressures to confirm the diagnosis, followed by definitive emergent fasciotomy, and finally delayed wound closure once tissue swelling subsides.
Acute compartment syndrome is a surgical emergency characterized by increased pressure within a closed fascial space, leading to microvascular compromise and tissue ischemia. The earliest and most sensitive clinical sign is severe pain out of proportion to the injury, which is exacerbated by passive stretch of the muscles in the affected compartment. It is critical to recognize that palpable pulses do not rule out compartment syndrome, as capillary perfusion pressure falls below tissue pressure long before the larger arteries are occluded. The first and most immediate step in management is to relieve any external compression by completely bivalving and removing the cast and underlying padding down to the skin. If clinical signs do not rapidly resolve, the next appropriate sequential step is measuring intracompartmental pressures (often assessed via delta pressure, calculated as diastolic blood pressure minus compartment pressure; a delta < 30 mm Hg is diagnostic). Once confirmed, definitive treatment requires emergent surgical decompression via a four-compartment fasciotomy of the lower leg. The surgical incisions are left open to accommodate ongoing tissue swelling and are subsequently managed with delayed primary closure or skin grafting 48 to 72 hours later.

Step-by-Step Solution

1
Complete removal of the cast and underlying padding down to the skin.
Rapid relief of extrinsic compressive forces on the injured limb.
External forces from tight casts or dressings are a major reversible cause of elevated compartment pressure; their immediate removal is the most critical initial intervention.
2
Measurement of intracompartmental tissue pressures.
Provides objective diagnostic confirmation of compartment syndrome.
If removing the cast does not result in rapid clinical improvement, tissue pressure measurement confirms the diagnosis (typically delta pressure < 30 mm Hg) prior to proceeding to invasive operative management.
3
Emergent four-compartment fasciotomy.
Surgical release of unyielding fascial boundaries.
Fasciotomy is the definitive treatment required to restore microvascular tissue perfusion and prevent irreversible ischemic muscle and nerve necrosis.
4
Delayed primary closure or split-thickness skin grafting.
Definitive closure of the surgical defect.
Fasciotomy incisions must be left open acutely to prevent recurrent pressure spikes from ongoing tissue swelling; closure is only safe once the underlying edema resolves.

Key Concept

The sequential management of acute compartment syndrome requires immediate removal of external constrictors, diagnostic confirmation via pressure measurement, definitive decompression via emergent fasciotomy, and subsequent delayed wound closure.
Question 1959Question →

An asymptomatic 24-year-old female presents to her primary care provider to establish care and undergo a health maintenance visit. She reports feeling well overall. Her only regular medication is a combined oral contraceptive pill. She reports becoming sexually active with a new male partner three months ago, noting inconsistent use of barrier protection. She has a lifetime history of three sexual partners. She has never smoked cigarettes or used illicit drugs. She denies abnormal vaginal discharge, dyspareunia, or genital lesions. A review of her electronic medical record indicates that she underwent a normal cervical cytology (Pap smear) at age 21, but has not had any other preventive screenings since that time. Physical examination reveals a normal cervix with no cervical motion tenderness or adnexal masses. Based on current guidelines, which of the following is the most appropriate screening strategy for this patient today?

Show answer & explanation

Answer: Cervical cytology and nucleic acid amplification testing for Chlamydia trachomatis and Neisseria gonorrhoeae

Answer

The most appropriate strategy is to perform cervical cytology alongside nucleic acid amplification testing for Chlamydia trachomatis and Neisseria gonorrhoeae.
The correct strategy combines two strongly indicated preventive measures for a 24-year-old sexually active woman: cervical cancer screening and STI screening. According to USPSTF guidelines, cervical cancer screening should commence at age 21 with cervical cytology alone every 3 years. Because this patient had her last cytology at age 21, she is exactly due for her next screening at age 24. Furthermore, the USPSTF and the CDC recommend annual screening for Chlamydia trachomatis and Neisseria gonorrhoeae in all sexually active women aged 24 years or younger, regardless of relationship status or contraceptive use.

Step-by-Step Solution

1
Determine the patient's requirement for cervical cancer screening based on her age and previous testing history.
The patient is 24 years old and her last normal cervical cytology was at age 21.
Guidelines state that cervical cancer screening should begin at age 21 and be repeated every 3 years with cytology alone until age 30. Therefore, a 3-year interval has elapsed, and she is due for cytology today.
2
Assess the need for human papillomavirus (HPV) testing.
HPV testing is not indicated for this patient.
HPV testing (either alone or as co-testing) is not recommended for average-risk women under the age of 30 because transient HPV infections are extremely common in this age group and most clear spontaneously without causing dysplasia.
3
Evaluate the patient's requirement for sexually transmitted infection (STI) screening based on her demographic and social history.
The patient is sexually active and under the age of 25, making her eligible for routine chlamydia and gonorrhea screening.
The USPSTF recommends annual screening for Chlamydia trachomatis and Neisseria gonorrhoeae in all sexually active women aged 24 years and younger.
4
Determine if any other routine STI serology is indicated.
Routine HSV serology is not indicated.
The USPSTF recommends against routine serologic screening for HSV in asymptomatic individuals due to a high rate of false positives and a lack of clinical utility in reducing transmission.

Key Concept

In average-risk women, cervical cytology is performed every 3 years from ages 21 to 29 without routine HPV testing; simultaneously, all sexually active women aged 24 and younger require annual screening for chlamydia and gonorrhea.
Question 1960Question →

A 62-year-old man is evaluated in the outpatient clinic for new-onset muscle pain and weakness. Two weeks ago, he was discharged from the hospital to complete a 6-week course of outpatient intravenous daptomycin for methicillin-resistant *Staphylococcus aureus* (MRSA) osteomyelitis of the right first metatarsal. He reports diffuse aching in his thighs, shoulders, and lower back that began 3 days ago and has progressively worsened. He now has difficulty climbing stairs. He has no chest pain, shortness of breath, or new focal neurologic deficits. His right foot wound is healing well with no erythema or purulent drainage.

Vital signs are within normal limits. Physical examination reveals diffuse proximal muscle tenderness and 4/54/5 strength in the bilateral hip flexors and shoulder abductors.

Laboratory evaluation shows:
Laboratory TestResultReference Range
Serum creatinine1.01.0 mg/dL0.7−1.30.7-1.3 mg/dL
Creatine phosphokinase (CPK)2,4502,450 U/L55−17055-170 U/L
Aspartate aminotransferase (AST)8585 U/L10−4010-40 U/L
Alanine aminotransferase (ALT)4242 U/L10−4010-40 U/L

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Discontinue daptomycin and initiate intravenous vancomycin

Answer

Discontinue daptomycin and initiate intravenous vancomycin
The correct answer is to discontinue daptomycin and initiate intravenous vancomycin. Daptomycin is associated with skeletal muscle toxicity, ranging from asymptomatic CPK elevation to severe rhabdomyolysis. Guidelines require baseline and weekly CPK monitoring during therapy. Daptomycin should be permanently discontinued if a patient develops unexplained signs or symptoms of myopathy (e.g., muscle aches, weakness) in conjunction with a CPK elevation greater than 55 times the upper limit of normal (ULN), or an asymptomatic CPK elevation greater than 1010 times the ULN. This patient is highly symptomatic and has a CPK >14>14 times the ULN. Because he is only two weeks into a six-week course for MRSA osteomyelitis, an alternative bactericidal agent with adequate bone penetration, such as intravenous vancomycin, must be promptly initiated.

Step-by-Step Solution

1
Analyze the clinical presentation and medication history.
The patient developed diffuse proximal muscle weakness and extreme CPK elevation while receiving daptomycin therapy.
Daptomycin is a lipopeptide antibiotic known to cause dose-dependent myopathy and rhabdomyolysis, requiring routine CPK monitoring.
2
Evaluate the laboratory findings to identify the source of abnormalities.
CPK is markedly elevated (>14>14 times the upper limit of normal). AST is mildly elevated while ALT is near normal.
The AST elevation is secondary to skeletal muscle breakdown, not hepatotoxicity. The profound CPK elevation combined with clinical symptoms confirms daptomycin-induced myopathy.
3
Determine the appropriate treatment modification.
Daptomycin must be discontinued immediately, and an alternative agent for MRSA osteomyelitis (such as vancomycin) must be initiated.
Continuing daptomycin when symptomatic myopathy is present risks severe rhabdomyolysis and acute kidney injury. Vancomycin provides necessary, appropriate coverage for the ongoing MRSA bone infection.

Key Concept

Patients receiving daptomycin require weekly monitoring of creatine phosphokinase (CPK) levels. The medication must be discontinued immediately if the patient develops symptomatic myopathy with a CPK >5>5 times the upper limit of normal, or an asymptomatic CPK elevation >10>10 times the upper limit of normal.
Estimated Time:1m 15s
PreviousPage 98 / 104Next
Patient Management Practice Questions — USMLE Step 3 — Page 98 | Examkin